Boothbay Fund Management’s Silence Therapeutics SLN Stock Holding History

Boothbay Fund Management’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.1M	Hold	209,088	–	–	0.01%	897
2025 Q4	$1.27M	Sell	209,088 -70,549	-25%	-$452K	0.02%	708
2025 Q3	$1.45M	Buy	279,637 +27,216	+11%	+$151K	0.02%	680
2025 Q2	$1.46M	Buy	252,421 +2,409	+1%	+$10.3K	0.03%	572
2025 Q1	$705K	Sell	250,012 -101,515	-29%	-$496K	0.02%	739
2024 Q4	$2.42M	Buy	351,527 +180,372	+105%	+$2.33M	0.06%	394
2024 Q3	$3.11M	Buy	171,155 +24,303	+17%	+$452K	0.07%	383
2024 Q2	$2.79M	Buy	146,852 +19,628	+15%	+$417K	0.07%	401
2024 Q1	$2.75M	Buy	+127,224	New	+$2.77M	0.05%	402

Other funds holding SLN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Boothbay Fund Management's SLN Position: Q1 2026 in Review

Boothbay Fund Management held its Silence Therapeutics (SLN) position steady in Q1 2026 at 209,088 shares worth $1.1M. The position accounts for 0.01% of the portfolio, ranked #897.

Boothbay Fund Management first reported a position in SLN in Q1 2024 and has held it in 9 quarters since. The position peaked at $3.11M in Q3 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

Boothbay Fund Management held 209,088 shares of Silence Therapeutics worth $1.1M as of Q1 2026.
Boothbay Fund Management left its Silence Therapeutics share count unchanged in Q1 2026.
Silence Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #897 holding.
Boothbay Fund Management first reported a position in Silence Therapeutics in Q1 2024 and has held it in 9 quarters since.
Boothbay Fund Management's Silence Therapeutics position peaked at $3.11M in Q3 2024.
56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.